
Cortexyme, Inc. – NASDAQ:CRTX
Cortexyme stock price today
Cortexyme stock price monthly change
Cortexyme stock price quarterly change
Cortexyme stock price yearly change
Cortexyme key metrics
Market Cap | 70.45M |
Enterprise value | N/A |
P/E | -0.65 |
EV/Sales | N/A |
EV/EBITDA | 0.05 |
Price/Sales | N/A |
Price/Book | 0.55 |
PEG ratio | 0.04 |
EPS | -4.47 |
Revenue | N/A |
EBITDA | -149.26M |
Income | -149.92M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCortexyme stock price history
Cortexyme stock forecast
Cortexyme financial statements
Sep 2021 | 0 | -21.70M | |
---|---|---|---|
Dec 2021 | 0 | -89.94M | |
Mar 2022 | 0 | -21.71M | |
Jun 2022 | 0 | -16.56M |
2022-03-01 | -0.65 | -0.78 |
---|
Sep 2021 | 147416000 | 14.76M | 10.02% |
---|---|---|---|
Dec 2021 | 133228000 | 14.64M | 10.99% |
Mar 2022 | 116130000 | 9.75M | 8.4% |
Jun 2022 | 117863000 | 6.33M | 5.37% |
Jun 2021 | -17.56M | 5.62M | 672K |
---|---|---|---|
Sep 2021 | -17.34M | 766K | 4.70M |
Dec 2021 | -14.41M | 20.91M | 990K |
Mar 2022 | -16.09M | 13.41M | 622K |
Cortexyme alternative data
Aug 2023 | 55 |
---|---|
Sep 2023 | 55 |
Oct 2023 | 55 |
Nov 2023 | 55 |
Dec 2023 | 55 |
Jan 2024 | 55 |
Feb 2024 | 55 |
Mar 2024 | 55 |
Apr 2024 | 55 |
May 2024 | 55 |
Jun 2024 | 55 |
Jul 2024 | 55 |
Cortexyme other data
Period | Buy | Sel |
---|---|---|
Jul 2021 | 0 | 116522 |
Aug 2021 | 0 | 38000 |
Oct 2021 | 0 | 5963 |
Nov 2021 | 763 | 0 |
Jun 2022 | 0 | 10800 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | MCDOWELL CARYN GORDON officer: Chief Le.. | Common Stock | 10,800 | $2.86 | $30,920 | ||
Option | LYNCH CASEY director, officer.. | Stock Option (Right to Buy) | 60,000 | $0.46 | $27,600 | ||
Option | LYNCH CASEY director, officer.. | Common Stock | 60,000 | $0.46 | $27,600 | ||
Option | LOWE CHRISTOPHER P. officer: COO & Chief Financial .. | Stock Option (right to buy) | 30,000 | $2.23 | $66,900 | ||
Option | LOWE CHRISTOPHER P. officer: COO & Chief Financial .. | Common Stock | 30,000 | $2.23 | $66,900 | ||
Purchase | DOMINY STEPHEN S. director, officer: Chief Scient.. | Common Stock | 763 | $14.4 | $10,987 | ||
Option | MCLOUGHLIN MARGARET director | Stock Option (right to buy) | 1,000 | $17 | $17,000 | ||
Sale | MCLOUGHLIN MARGARET director | Common Stock | 1,000 | $88.93 | $88,930 | ||
Option | MCLOUGHLIN MARGARET director | Common Stock | 1,000 | $17 | $17,000 | ||
Option | LOWE CHRISTOPHER P. officer: COO & Chief Financial .. | Stock Option (Right to Buy) | 4,963 | $54.85 | $272,221 |
Patent |
---|
Application Filling date: 20 Mar 2020 Issue date: 30 Jun 2022 |
Grant Utility: Inhibitors of lysine gingipain Filling date: 4 May 2020 Issue date: 17 May 2022 |
Grant Filling date: 11 Jun 2020 Issue date: 10 May 2022 |
Application Filling date: 27 Sep 2019 Issue date: 18 Nov 2021 |
Application Filling date: 8 Jul 2021 Issue date: 4 Nov 2021 |
Grant Filling date: 8 Nov 2019 Issue date: 13 Jul 2021 |
Application Filling date: 11 Jun 2020 Issue date: 25 Feb 2021 |
Grant Utility: Inhibitors of arginine gingipain Filling date: 9 May 2018 Issue date: 2 Feb 2021 |
Application Filling date: 4 May 2020 Issue date: 21 Jan 2021 |
Grant Filling date: 14 Mar 2019 Issue date: 4 Aug 2020 |
Quarter | Transcript |
---|---|
Q3 2013 7 Nov 2013 | Q3 2013 Earnings Call Transcript |
Q2 2013 6 Aug 2013 | Q2 2013 Earnings Call Transcript |
Q1 2013 9 May 2013 | Q1 2013 Earnings Call Transcript |
Q4 2012 14 Mar 2013 | Q4 2012 Earnings Call Transcript |
Insider | Compensation |
---|---|
Ms. Casey C. Lynch (1974) Co-Founder, Chairman, Pres & Chief Executive Officer | $787,500 |
Dr. Michael J. Detke M.D., Ph.D. (1967) Chief Medical Officer | $574,000 |
Dr. Leslie J. Holsinger Ph.D. (1965) Executive Vice President of R&D | $567,000 |
Mr. Christopher P. Lowe M.B.A. (1971) Chief Operating Officer, Chief Financial Officer & Treasurer | $546,000 |
Ms. Caryn Gordon McDowell (1970) Chief Legal & Admin. Officer and Corporation Sec. | $513,160 |
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Cortexyme: A Challenging Path Forward
Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Cortexyme: Alzheimer's Readout In November A Binary Event
Biogen Controversy And The Spillover Effect: Actionable Insights
-
What's the price of Cortexyme stock today?
One share of Cortexyme stock can currently be purchased for approximately $1.95.
-
When is Cortexyme's next earnings date?
Unfortunately, Cortexyme's (CRTX) next earnings date is currently unknown.
-
Does Cortexyme pay dividends?
No, Cortexyme does not pay dividends.
-
How much money does Cortexyme make?
Cortexyme has a market capitalization of 70.45M. Cortexyme made a loss 89.95M US dollars in net income (profit) last year or -$0.78 on an earnings per share basis.
-
What is Cortexyme's stock symbol?
Cortexyme, Inc. is traded on the NASDAQ under the ticker symbol "CRTX".
-
What is Cortexyme's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cortexyme?
Shares of Cortexyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cortexyme's key executives?
Cortexyme's management team includes the following people:
- Ms. Casey C. Lynch Co-Founder, Chairman, Pres & Chief Executive Officer(age: 51, pay: $787,500)
- Dr. Michael J. Detke M.D., Ph.D. Chief Medical Officer(age: 58, pay: $574,000)
- Dr. Leslie J. Holsinger Ph.D. Executive Vice President of R&D(age: 60, pay: $567,000)
- Mr. Christopher P. Lowe M.B.A. Chief Operating Officer, Chief Financial Officer & Treasurer(age: 54, pay: $546,000)
- Ms. Caryn Gordon McDowell Chief Legal & Admin. Officer and Corporation Sec.(age: 55, pay: $513,160)
-
Is Cortexyme founder-led company?
Yes, Cortexyme is a company led by its founder Ms. Casey C. Lynch.
-
How many employees does Cortexyme have?
As Jul 2024, Cortexyme employs 55 workers.
-
When Cortexyme went public?
Cortexyme, Inc. is publicly traded company for more then 6 years since IPO on 9 May 2019.
-
What is Cortexyme's official website?
The official website for Cortexyme is cortexyme.com.
-
Where are Cortexyme's headquarters?
Cortexyme is headquartered at 269 E Grand Ave, South San Francisco, CALIFORNIA.
-
How can i contact Cortexyme?
Cortexyme's mailing address is 269 E Grand Ave, South San Francisco, CALIFORNIA and company can be reached via phone at +1 415 910 5717.
Cortexyme company profile:

Cortexyme, Inc.
cortexyme.comNASDAQ
55
Biotechnology
Healthcare
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
South San Francisco, CALIFORNIA 94080
CIK: 0001662774
ISIN: US22053A1079
CUSIP: 22053A107